The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Cancer Molecular Biomarkers Market Research Report 2025
Synopsis
Cancer molecular biomarkers refer to naturally-occurring molecules or genes in living organisms, which is an indicator for the presence of cancer in the body.A biomarker is a measurable indicator of biological process, condition, or disease and can be found in the blood, tissues, or other body fluids. Cancer molecular biomarkers help to diagnose cancer and monitor patients’ responses to treatments.
The global Cancer Molecular Biomarkers market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Factors such as technological advancements, increasing research and development activities, increase in funding from various government and non-government organizations, rise in healthcare expenditure, non invasive technology, increasing incidences of cancer, and streamlined drug delivery process are expected to drive the market for cancer molecular biomarkers .In addition, growing survival rates and increased accuracy of diagnosis with the help of biomarkers are expected to drive market for cancer molecular biomarkers.
This report aims to provide a comprehensive presentation of the global market for Cancer Molecular Biomarkers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Molecular Biomarkers.
Report Scope
The Cancer Molecular Biomarkers market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Molecular Biomarkers market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Molecular Biomarkers companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Correlogic Systems
AgendiaBv
BioMerieux
Aureon Laboratories
Astellas Pharma US
Becton
Diadexus
Abbott Laboratories
Affymetrix
Clarient
Biomoda
Beckman Coulter
Dickinson
Segment by Type
Genetic Methods
Protein Methods
Imaging
Segment by Application
Pharmaceutical
Medical Laboratory
Hospital
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Molecular Biomarkers companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Cancer molecular biomarkers refer to naturally-occurring molecules or genes in living organisms, which is an indicator for the presence of cancer in the body.A biomarker is a measurable indicator of biological process, condition, or disease and can be found in the blood, tissues, or other body fluids. Cancer molecular biomarkers help to diagnose cancer and monitor patients’ responses to treatments.
The global Cancer Molecular Biomarkers market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Factors such as technological advancements, increasing research and development activities, increase in funding from various government and non-government organizations, rise in healthcare expenditure, non invasive technology, increasing incidences of cancer, and streamlined drug delivery process are expected to drive the market for cancer molecular biomarkers .In addition, growing survival rates and increased accuracy of diagnosis with the help of biomarkers are expected to drive market for cancer molecular biomarkers.
This report aims to provide a comprehensive presentation of the global market for Cancer Molecular Biomarkers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Molecular Biomarkers.
Report Scope
The Cancer Molecular Biomarkers market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Molecular Biomarkers market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Molecular Biomarkers companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Correlogic Systems
AgendiaBv
BioMerieux
Aureon Laboratories
Astellas Pharma US
Becton
Diadexus
Abbott Laboratories
Affymetrix
Clarient
Biomoda
Beckman Coulter
Dickinson
Segment by Type
Genetic Methods
Protein Methods
Imaging
Segment by Application
Pharmaceutical
Medical Laboratory
Hospital
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Molecular Biomarkers companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Molecular Biomarkers Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Genetic Methods
1.2.3 Protein Methods
1.2.4 Imaging
1.3 Market by Application
1.3.1 Global Cancer Molecular Biomarkers Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical
1.3.3 Medical Laboratory
1.3.4 Hospital
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer Molecular Biomarkers Market Perspective (2019-2030)
2.2 Cancer Molecular Biomarkers Growth Trends by Region
2.2.1 Global Cancer Molecular Biomarkers Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Cancer Molecular Biomarkers Historic Market Size by Region (2019-2024)
2.2.3 Cancer Molecular Biomarkers Forecasted Market Size by Region (2025-2030)
2.3 Cancer Molecular Biomarkers Market Dynamics
2.3.1 Cancer Molecular Biomarkers Industry Trends
2.3.2 Cancer Molecular Biomarkers Market Drivers
2.3.3 Cancer Molecular Biomarkers Market Challenges
2.3.4 Cancer Molecular Biomarkers Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Molecular Biomarkers Players by Revenue
3.1.1 Global Top Cancer Molecular Biomarkers Players by Revenue (2019-2024)
3.1.2 Global Cancer Molecular Biomarkers Revenue Market Share by Players (2019-2024)
3.2 Global Cancer Molecular Biomarkers Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cancer Molecular Biomarkers Revenue
3.4 Global Cancer Molecular Biomarkers Market Concentration Ratio
3.4.1 Global Cancer Molecular Biomarkers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Molecular Biomarkers Revenue in 2023
3.5 Cancer Molecular Biomarkers Key Players Head office and Area Served
3.6 Key Players Cancer Molecular Biomarkers Product Solution and Service
3.7 Date of Enter into Cancer Molecular Biomarkers Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Molecular Biomarkers Breakdown Data by Type
4.1 Global Cancer Molecular Biomarkers Historic Market Size by Type (2019-2024)
4.2 Global Cancer Molecular Biomarkers Forecasted Market Size by Type (2025-2030)
5 Cancer Molecular Biomarkers Breakdown Data by Application
5.1 Global Cancer Molecular Biomarkers Historic Market Size by Application (2019-2024)
5.2 Global Cancer Molecular Biomarkers Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Cancer Molecular Biomarkers Market Size (2019-2030)
6.2 North America Cancer Molecular Biomarkers Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Cancer Molecular Biomarkers Market Size by Country (2019-2024)
6.4 North America Cancer Molecular Biomarkers Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cancer Molecular Biomarkers Market Size (2019-2030)
7.2 Europe Cancer Molecular Biomarkers Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Cancer Molecular Biomarkers Market Size by Country (2019-2024)
7.4 Europe Cancer Molecular Biomarkers Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Molecular Biomarkers Market Size (2019-2030)
8.2 Asia-Pacific Cancer Molecular Biomarkers Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Cancer Molecular Biomarkers Market Size by Region (2019-2024)
8.4 Asia-Pacific Cancer Molecular Biomarkers Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cancer Molecular Biomarkers Market Size (2019-2030)
9.2 Latin America Cancer Molecular Biomarkers Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Cancer Molecular Biomarkers Market Size by Country (2019-2024)
9.4 Latin America Cancer Molecular Biomarkers Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Molecular Biomarkers Market Size (2019-2030)
10.2 Middle East & Africa Cancer Molecular Biomarkers Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Cancer Molecular Biomarkers Market Size by Country (2019-2024)
10.4 Middle East & Africa Cancer Molecular Biomarkers Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Correlogic Systems
11.1.1 Correlogic Systems Company Detail
11.1.2 Correlogic Systems Business Overview
11.1.3 Correlogic Systems Cancer Molecular Biomarkers Introduction
11.1.4 Correlogic Systems Revenue in Cancer Molecular Biomarkers Business (2019-2024)
11.1.5 Correlogic Systems Recent Development
11.2 AgendiaBv
11.2.1 AgendiaBv Company Detail
11.2.2 AgendiaBv Business Overview
11.2.3 AgendiaBv Cancer Molecular Biomarkers Introduction
11.2.4 AgendiaBv Revenue in Cancer Molecular Biomarkers Business (2019-2024)
11.2.5 AgendiaBv Recent Development
11.3 BioMerieux
11.3.1 BioMerieux Company Detail
11.3.2 BioMerieux Business Overview
11.3.3 BioMerieux Cancer Molecular Biomarkers Introduction
11.3.4 BioMerieux Revenue in Cancer Molecular Biomarkers Business (2019-2024)
11.3.5 BioMerieux Recent Development
11.4 Aureon Laboratories
11.4.1 Aureon Laboratories Company Detail
11.4.2 Aureon Laboratories Business Overview
11.4.3 Aureon Laboratories Cancer Molecular Biomarkers Introduction
11.4.4 Aureon Laboratories Revenue in Cancer Molecular Biomarkers Business (2019-2024)
11.4.5 Aureon Laboratories Recent Development
11.5 Astellas Pharma US
11.5.1 Astellas Pharma US Company Detail
11.5.2 Astellas Pharma US Business Overview
11.5.3 Astellas Pharma US Cancer Molecular Biomarkers Introduction
11.5.4 Astellas Pharma US Revenue in Cancer Molecular Biomarkers Business (2019-2024)
11.5.5 Astellas Pharma US Recent Development
11.6 Becton
11.6.1 Becton Company Detail
11.6.2 Becton Business Overview
11.6.3 Becton Cancer Molecular Biomarkers Introduction
11.6.4 Becton Revenue in Cancer Molecular Biomarkers Business (2019-2024)
11.6.5 Becton Recent Development
11.7 Diadexus
11.7.1 Diadexus Company Detail
11.7.2 Diadexus Business Overview
11.7.3 Diadexus Cancer Molecular Biomarkers Introduction
11.7.4 Diadexus Revenue in Cancer Molecular Biomarkers Business (2019-2024)
11.7.5 Diadexus Recent Development
11.8 Abbott Laboratories
11.8.1 Abbott Laboratories Company Detail
11.8.2 Abbott Laboratories Business Overview
11.8.3 Abbott Laboratories Cancer Molecular Biomarkers Introduction
11.8.4 Abbott Laboratories Revenue in Cancer Molecular Biomarkers Business (2019-2024)
11.8.5 Abbott Laboratories Recent Development
11.9 Affymetrix
11.9.1 Affymetrix Company Detail
11.9.2 Affymetrix Business Overview
11.9.3 Affymetrix Cancer Molecular Biomarkers Introduction
11.9.4 Affymetrix Revenue in Cancer Molecular Biomarkers Business (2019-2024)
11.9.5 Affymetrix Recent Development
11.10 Clarient
11.10.1 Clarient Company Detail
11.10.2 Clarient Business Overview
11.10.3 Clarient Cancer Molecular Biomarkers Introduction
11.10.4 Clarient Revenue in Cancer Molecular Biomarkers Business (2019-2024)
11.10.5 Clarient Recent Development
11.11 Biomoda
11.11.1 Biomoda Company Detail
11.11.2 Biomoda Business Overview
11.11.3 Biomoda Cancer Molecular Biomarkers Introduction
11.11.4 Biomoda Revenue in Cancer Molecular Biomarkers Business (2019-2024)
11.11.5 Biomoda Recent Development
11.12 Beckman Coulter
11.12.1 Beckman Coulter Company Detail
11.12.2 Beckman Coulter Business Overview
11.12.3 Beckman Coulter Cancer Molecular Biomarkers Introduction
11.12.4 Beckman Coulter Revenue in Cancer Molecular Biomarkers Business (2019-2024)
11.12.5 Beckman Coulter Recent Development
11.13 Dickinson
11.13.1 Dickinson Company Detail
11.13.2 Dickinson Business Overview
11.13.3 Dickinson Cancer Molecular Biomarkers Introduction
11.13.4 Dickinson Revenue in Cancer Molecular Biomarkers Business (2019-2024)
11.13.5 Dickinson Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Cancer Molecular Biomarkers Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Genetic Methods
Table 3. Key Players of Protein Methods
Table 4. Key Players of Imaging
Table 5. Global Cancer Molecular Biomarkers Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Cancer Molecular Biomarkers Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Cancer Molecular Biomarkers Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Cancer Molecular Biomarkers Market Share by Region (2019-2024)
Table 9. Global Cancer Molecular Biomarkers Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Cancer Molecular Biomarkers Market Share by Region (2025-2030)
Table 11. Cancer Molecular Biomarkers Market Trends
Table 12. Cancer Molecular Biomarkers Market Drivers
Table 13. Cancer Molecular Biomarkers Market Challenges
Table 14. Cancer Molecular Biomarkers Market Restraints
Table 15. Global Cancer Molecular Biomarkers Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Cancer Molecular Biomarkers Market Share by Players (2019-2024)
Table 17. Global Top Cancer Molecular Biomarkers Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Molecular Biomarkers as of 2023)
Table 18. Ranking of Global Top Cancer Molecular Biomarkers Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Cancer Molecular Biomarkers Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Cancer Molecular Biomarkers Product Solution and Service
Table 22. Date of Enter into Cancer Molecular Biomarkers Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Cancer Molecular Biomarkers Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Cancer Molecular Biomarkers Revenue Market Share by Type (2019-2024)
Table 26. Global Cancer Molecular Biomarkers Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Cancer Molecular Biomarkers Revenue Market Share by Type (2025-2030)
Table 28. Global Cancer Molecular Biomarkers Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Cancer Molecular Biomarkers Revenue Market Share by Application (2019-2024)
Table 30. Global Cancer Molecular Biomarkers Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Cancer Molecular Biomarkers Revenue Market Share by Application (2025-2030)
Table 32. North America Cancer Molecular Biomarkers Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Cancer Molecular Biomarkers Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Cancer Molecular Biomarkers Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Cancer Molecular Biomarkers Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Cancer Molecular Biomarkers Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Cancer Molecular Biomarkers Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Cancer Molecular Biomarkers Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Cancer Molecular Biomarkers Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Cancer Molecular Biomarkers Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Cancer Molecular Biomarkers Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Cancer Molecular Biomarkers Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Cancer Molecular Biomarkers Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Cancer Molecular Biomarkers Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Cancer Molecular Biomarkers Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Cancer Molecular Biomarkers Market Size by Country (2025-2030) & (US$ Million)
Table 47. Correlogic Systems Company Detail
Table 48. Correlogic Systems Business Overview
Table 49. Correlogic Systems Cancer Molecular Biomarkers Product
Table 50. Correlogic Systems Revenue in Cancer Molecular Biomarkers Business (2019-2024) & (US$ Million)
Table 51. Correlogic Systems Recent Development
Table 52. AgendiaBv Company Detail
Table 53. AgendiaBv Business Overview
Table 54. AgendiaBv Cancer Molecular Biomarkers Product
Table 55. AgendiaBv Revenue in Cancer Molecular Biomarkers Business (2019-2024) & (US$ Million)
Table 56. AgendiaBv Recent Development
Table 57. BioMerieux Company Detail
Table 58. BioMerieux Business Overview
Table 59. BioMerieux Cancer Molecular Biomarkers Product
Table 60. BioMerieux Revenue in Cancer Molecular Biomarkers Business (2019-2024) & (US$ Million)
Table 61. BioMerieux Recent Development
Table 62. Aureon Laboratories Company Detail
Table 63. Aureon Laboratories Business Overview
Table 64. Aureon Laboratories Cancer Molecular Biomarkers Product
Table 65. Aureon Laboratories Revenue in Cancer Molecular Biomarkers Business (2019-2024) & (US$ Million)
Table 66. Aureon Laboratories Recent Development
Table 67. Astellas Pharma US Company Detail
Table 68. Astellas Pharma US Business Overview
Table 69. Astellas Pharma US Cancer Molecular Biomarkers Product
Table 70. Astellas Pharma US Revenue in Cancer Molecular Biomarkers Business (2019-2024) & (US$ Million)
Table 71. Astellas Pharma US Recent Development
Table 72. Becton Company Detail
Table 73. Becton Business Overview
Table 74. Becton Cancer Molecular Biomarkers Product
Table 75. Becton Revenue in Cancer Molecular Biomarkers Business (2019-2024) & (US$ Million)
Table 76. Becton Recent Development
Table 77. Diadexus Company Detail
Table 78. Diadexus Business Overview
Table 79. Diadexus Cancer Molecular Biomarkers Product
Table 80. Diadexus Revenue in Cancer Molecular Biomarkers Business (2019-2024) & (US$ Million)
Table 81. Diadexus Recent Development
Table 82. Abbott Laboratories Company Detail
Table 83. Abbott Laboratories Business Overview
Table 84. Abbott Laboratories Cancer Molecular Biomarkers Product
Table 85. Abbott Laboratories Revenue in Cancer Molecular Biomarkers Business (2019-2024) & (US$ Million)
Table 86. Abbott Laboratories Recent Development
Table 87. Affymetrix Company Detail
Table 88. Affymetrix Business Overview
Table 89. Affymetrix Cancer Molecular Biomarkers Product
Table 90. Affymetrix Revenue in Cancer Molecular Biomarkers Business (2019-2024) & (US$ Million)
Table 91. Affymetrix Recent Development
Table 92. Clarient Company Detail
Table 93. Clarient Business Overview
Table 94. Clarient Cancer Molecular Biomarkers Product
Table 95. Clarient Revenue in Cancer Molecular Biomarkers Business (2019-2024) & (US$ Million)
Table 96. Clarient Recent Development
Table 97. Biomoda Company Detail
Table 98. Biomoda Business Overview
Table 99. Biomoda Cancer Molecular Biomarkers Product
Table 100. Biomoda Revenue in Cancer Molecular Biomarkers Business (2019-2024) & (US$ Million)
Table 101. Biomoda Recent Development
Table 102. Beckman Coulter Company Detail
Table 103. Beckman Coulter Business Overview
Table 104. Beckman Coulter Cancer Molecular Biomarkers Product
Table 105. Beckman Coulter Revenue in Cancer Molecular Biomarkers Business (2019-2024) & (US$ Million)
Table 106. Beckman Coulter Recent Development
Table 107. Dickinson Company Detail
Table 108. Dickinson Business Overview
Table 109. Dickinson Cancer Molecular Biomarkers Product
Table 110. Dickinson Revenue in Cancer Molecular Biomarkers Business (2019-2024) & (US$ Million)
Table 111. Dickinson Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cancer Molecular Biomarkers Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Cancer Molecular Biomarkers Market Share by Type: 2023 VS 2030
Figure 3. Genetic Methods Features
Figure 4. Protein Methods Features
Figure 5. Imaging Features
Figure 6. Global Cancer Molecular Biomarkers Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Cancer Molecular Biomarkers Market Share by Application: 2023 VS 2030
Figure 8. Pharmaceutical Case Studies
Figure 9. Medical Laboratory Case Studies
Figure 10. Hospital Case Studies
Figure 11. Cancer Molecular Biomarkers Report Years Considered
Figure 12. Global Cancer Molecular Biomarkers Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Cancer Molecular Biomarkers Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Cancer Molecular Biomarkers Market Share by Region: 2023 VS 2030
Figure 15. Global Cancer Molecular Biomarkers Market Share by Players in 2023
Figure 16. Global Top Cancer Molecular Biomarkers Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Molecular Biomarkers as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Cancer Molecular Biomarkers Revenue in 2023
Figure 18. North America Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Cancer Molecular Biomarkers Market Share by Country (2019-2030)
Figure 20. United States Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Cancer Molecular Biomarkers Market Share by Country (2019-2030)
Figure 24. Germany Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Cancer Molecular Biomarkers Market Share by Region (2019-2030)
Figure 32. China Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Cancer Molecular Biomarkers Market Share by Country (2019-2030)
Figure 40. Mexico Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Cancer Molecular Biomarkers Market Share by Country (2019-2030)
Figure 44. Turkey Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Cancer Molecular Biomarkers Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Correlogic Systems Revenue Growth Rate in Cancer Molecular Biomarkers Business (2019-2024)
Figure 47. AgendiaBv Revenue Growth Rate in Cancer Molecular Biomarkers Business (2019-2024)
Figure 48. BioMerieux Revenue Growth Rate in Cancer Molecular Biomarkers Business (2019-2024)
Figure 49. Aureon Laboratories Revenue Growth Rate in Cancer Molecular Biomarkers Business (2019-2024)
Figure 50. Astellas Pharma US Revenue Growth Rate in Cancer Molecular Biomarkers Business (2019-2024)
Figure 51. Becton Revenue Growth Rate in Cancer Molecular Biomarkers Business (2019-2024)
Figure 52. Diadexus Revenue Growth Rate in Cancer Molecular Biomarkers Business (2019-2024)
Figure 53. Abbott Laboratories Revenue Growth Rate in Cancer Molecular Biomarkers Business (2019-2024)
Figure 54. Affymetrix Revenue Growth Rate in Cancer Molecular Biomarkers Business (2019-2024)
Figure 55. Clarient Revenue Growth Rate in Cancer Molecular Biomarkers Business (2019-2024)
Figure 56. Biomoda Revenue Growth Rate in Cancer Molecular Biomarkers Business (2019-2024)
Figure 57. Beckman Coulter Revenue Growth Rate in Cancer Molecular Biomarkers Business (2019-2024)
Figure 58. Dickinson Revenue Growth Rate in Cancer Molecular Biomarkers Business (2019-2024)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
